121 related articles for article (PubMed ID: 31962100)
1. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
2. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems.
Barbour M; Wood R; Harte T; Bushell TJ; Jiang HR
Immunology; 2022 Mar; 165(3):312-327. PubMed ID: 34826154
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD52 blocks EAE independent of PD-1 signals and promotes repopulation dominated by double-negative T cells and newly generated T and B cells.
Haile Y; Adegoke A; Laribi B; Lin J; Anderson CC
Eur J Immunol; 2020 Sep; 50(9):1362-1373. PubMed ID: 32388861
[TBL] [Abstract][Full Text] [Related]
6. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
[TBL] [Abstract][Full Text] [Related]
8. A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali L; Saxena G; Jones M; Leisegang GR; Gammon L; Gnanapavan S; Giovannoni G; Schmierer K; Baker D; Kang AS
Biotechniques; 2020 Apr; 68(4):185-190. PubMed ID: 32096651
[No Abstract] [Full Text] [Related]
9. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
Demir S; Pitarokoili K; Linker R; Gold R
J Neuroimmunol; 2019 Mar; 328():78-85. PubMed ID: 30623801
[TBL] [Abstract][Full Text] [Related]
10. CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis.
Bogie JF; Grajchen E; Wouters E; Broux B; Stinissen P; Van Wijmeersch B; Hendriks JJ
Ther Adv Chronic Dis; 2020; 11():2040622320947378. PubMed ID: 32913622
[TBL] [Abstract][Full Text] [Related]
11. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.
Baker D; Ali L; Saxena G; Pryce G; Jones M; Schmierer K; Giovannoni G; Gnanapavan S; Munger KC; Samkoff L; Goodman A; Kang AS
Front Immunol; 2020; 11():124. PubMed ID: 32117274
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
[TBL] [Abstract][Full Text] [Related]
13. Different fermentation processes produced variants of an anti-CD52 monoclonal antibody that have divergent in vitro and in vivo characteristics.
Zhuang C; Zheng C; Chen Y; Huang Z; Wang Y; Fu Q; Zeng C; Wu T; Yang L; Qi N
Appl Microbiol Biotechnol; 2017 Aug; 101(15):5997-6006. PubMed ID: 28512676
[TBL] [Abstract][Full Text] [Related]
14. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Turner MJ; Pang PT; Chretien N; Havari E; LaMorte MJ; Oliver J; Pande N; Masterjohn E; Carter K; Reczek D; Brondyk W; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2015 Aug; 285():4-12. PubMed ID: 26198912
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss.
Gushchina S; Pryce G; Yip PK; Wu D; Pallier P; Giovannoni G; Baker D; Bo X
Glia; 2018 Oct; 66(10):2108-2125. PubMed ID: 30144320
[TBL] [Abstract][Full Text] [Related]
16. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
Qi J; Chen SS; Chiorazzi N; Rader C
Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
[TBL] [Abstract][Full Text] [Related]
17. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
[TBL] [Abstract][Full Text] [Related]
18. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
19. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
20. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]